Multiple Choice
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
A) Decreased therapeutic levels of quinidine
B) Increased therapeutic levels of quinidine
C) Decreased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination
D) Increased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination
Correct Answer:
Verified
Correct Answer:
Verified
Q2: Ultra-rapid metabolizers of drugs may have:<br>A) To
Q3: Genetic polymorphisms account for differences in metabolism,
Q4: Carbamazepine has a Black Box Warning recommending
Q5: Warfarin resistance may be seen in patients
Q6: A provider may consider testing for CYP2D6
Q7: Patients who have a poor metabolism phenotype
Q8: Rifampin is a nonspecific CYP450 inducer that
Q9: Up to 21% of Asians are ultra-rapid
Q11: Pharmacogenetic testing is required by the U.S.
Q12: Genetic testing for VCORC1 mutation to assess